

ongoing trials - trial from [www.clinicaltrials.gov](http://www.clinicaltrials.gov)

## **Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicafort/Navocafort/ABBV-119 Combination Therapy in Adult Participants With Cystic Fibrosis - Phase 2 - Not yet recruiting**

**Code:** NCT04853368

**Year:** 2021

**Date:** June 29, 2021

**Author:** AbbVie

### **Study design (if review, criteria of inclusion for studies)**

Interventional - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment

### **Participants**

Cystic Fibrosis (CF) - 18 Years and older (Adult, Older Adult)

### **Interventions**

Drug: Galicafort|Drug: Placebo|Drug: Navocafort|Drug: ABBV-119

### **Outcome measures**

Absolute Change From Baseline in ppFEV1|Absolute Change From Baseline in Sweat Chloride (SwCl)|Absolute Change From Baseline in Forced Vital Capacity [FVC]|Absolute Change From Baseline in Forced Expiratory Flow at Mid-Lung Capacity [FEF25-75]|Relative Changes From Baseline in ppFEV1|Relative Changes From Baseline in FVC|Relative Changes From Baseline in FEF25-75|Absolute Change in CF Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline

<https://ClinicalTrials.gov/show/NCT04853368>

### **Keywords**

Adult; Aminophenols; CFTR Modulators; Genetic Predisposition to Disease; pharmacological\_intervention; Galicafort; Navocafort; ABBV119;